This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, in ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...

Structure Therapeutics' GSBR-1290 showed a ... zepbound and mounjaro. Here’s ozempic (semaglutide) data: The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Key drugs in this category include Novo Nordisk’s Ozempic (semaglutide ... Viking Therapeutics ($5.2bn), Structure Therapeutics ($1.8bn) and Altimmune ($642m) are small- to mid-cap companies ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...